

Spanish National Securities Market Commission (CNMV)  
Attn: Markets Directorate General  
c/ Edison núm. 4  
28006 Madrid

Madrid, February 28, 2022

In accordance with article 227 of the recast Spanish Securities Market Act (texto refundido de la Ley del Mercado de Valores), is hereby reported the following:

### **OTHER RELEVANT INFORMATION**

The Board of Directors of Pharma Mar, S.A., at its meeting held today, has adopted, among others, the following resolutions and decisions:

1. To draw up and subscribe the Annual Financial Statements (Balance Sheet, Profit and Loss Account, Statement of Changes in Net Equity and Cash Flow Statement, and Annual Report) and Management Report for fiscal year ended on December 31, 2021, both of Pharma Mar, S.A. and its Consolidated Group, as well as the separate report on the status of consolidated non-financial information for the fiscal year 2021, referred to in article 49.7 of the Commercial Code, which forms part of the Management Report.
2. To propose the distribution to the shareholders, subject to the approval of the General Shareholders Meeting, of a dividend charged to the profit of the fiscal year ended on December 31, 2021 in relation to the individual accounts of Pharma Mar, S.A. for a cash amount of EUR 0.65 gross per share of Pharma Mar, S.A. entitled to receive it, deducting withholding tax applicable at the time of payment of said amount.
3. To approve and publish the Annual Corporate Governance Report and the Annual Report on director's remunerations, in both cases, for the year ended December 31, 2021.
4. To amend articles 5.3.b (vii), 14.2, 17 bis and 29.2 and approve a new revised text of the Board of Directors Regulations of the Company, in order to (i) adequately establish in this body of regulations the function of the Audit Committee to report on related-party transactions that must be approved by the general shareholders' meeting or the board of directors, which was attributed to the aforementioned Committee in the previous reform of the Regulations of the Board approved on 29 July 2021; (ii) to faithfully reflect the content of recommendation 14 of the Good Governance Code of Listed Companies, in relation to the annual verification by the Appointments and Compensation and Sustainability Committee of compliance with the policy for the selection of directors; and Recommendation 50 of the Good Governance Code, in relation to the functions of verification of compliance with the remuneration policy established by the Company and the periodic review of the remuneration policy applied to directors and senior management, by the aforementioned Committee; and (iii) in relation to the evaluation of the Board of Directors, to allow the Company to have the optional assistance of external consultants for each annual evaluation, and not necessarily be subject to a predetermined periodicity, which Recommendation 36 of the Good Governance Code establishes as three years.

The new consolidated text of the Pharma Mar, S.A. Board of Directors Regulations will be reported today to CNMV through the authorized procedure. Moreover, it will be filed for registration within the Madrid Mercantile Registry, and submitted for information at the next General Shareholders Meeting.

5. Pharma Mar will host a conference call and webcast for investors and analysts on Tuesday, March 1, 2022, at 13.00 CET. The numbers to connect to the teleconference are +34 91 901 16 44 (from Spain) +1 646 664 1960 (from USA or Canada) and +44 20 3936 2999 (other countries). Participants' access code: 146916.

Interested parties can also follow the conference call live via the following link:  
<https://streamstudio.world-television.com/1052-1618-31859/en>

The teleconference and the recording of the conference call can be accessed on Pharma Mar's website by visiting the [Events Calendar](#) section of the company's website at [www.pharmamar.com](http://www.pharmamar.com)